Download PDF
Klin Monbl Augenheilkd 2018; 235(05): 562-567
DOI: 10.1055/a-0586-3931
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Konventionelle synthetische Immunsuppressiva (DMARDs) für die Therapie der nichtinfektiösen Uveitis

Conventional Synthetic Disease-modifying Antirheumatic Drugs (DMARDs) for the Treatment of Non-infectious Uveitis
Christoph Tappeiner
1   Universitätsklinik für Augenheilkunde, Inselspital, Bern, Schweiz
,
Thomas Rath
2   1. Medizinische Klinik, St. Franziskus-Hospital, Münster
,
Arnd Heiligenhaus
3   Augenabteilung, St. Franziskus-Hospital, Münster
› Author Affiliations
Further Information

Publication History

eingereicht 23 December 2017

akzeptiert 26 February 2018

Publication Date:
08 May 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Initialtherapie von Uveitiden besteht aus einer topischen und/oder systemischen Kortikosteroidgabe. Zur Erzielung von dauerhafter Reizfreiheit, Prophylaxe von uveitischen Sekundärkomplikationen, Kortisoneinsparung und Vermeidung von kortikosteroidbedingten unerwünschten Arzneimittelwirkungen ist im weiteren Verlauf nicht selten der Einsatz einer krankheitsmodifizierenden Therapie (sog. disease modifying antirheumatic drugs, DMARDs) notwendig. Dieser Beitrag soll eine strukturierte Übersicht über die wichtigsten konventionellen synthetischen DMARDs, deren Indikation, mögliche unerwünschte Arzneimittelwirkungen und das interdisziplinäre Monitoring vermitteln.

Abstract

The first-line therapy of uveitis normally consists of topical and/or systemic corticosteroid use. To achieve long-term ocular quiescence, to prevent uveitic secondary complications, to allow corticosteroid sparing and to avoid corticosteroid-related adverse effects, the application of immunosuppressive drugs (disease modifying antirheumatic drugs; DMARDs) is often necessary during the course of the disease. This article presents a structural overview of the most important conventional synthetic DMARDs, their indication, adverse events and interdisciplinary monitoring.

Schlüsselwörter

konventionelle synthetische DMARDs - nichtinfektiöse Uveitis - Therapie - Monitoring - unerwünschte Arzneimittelwirkungen

Key words

conventional synthetic disease modifying antirheumatic drugs (csDMARD) - non-infectious uveitis - treatment - monitoring - adverse events
 

  • Literatur

  • 1 Jabs DA, Rosenbaum JT, Foster CS. et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000; 130: 492-513
    CrossrefPubMedGoogle Scholar
  • 2 Jabs DA. Immunosuppression for the uveitides. Ophthalmology 2018; 125: 193-202 doi:10.1016/j.ophth.2017.08.007
    CrossrefPubMedGoogle Scholar
  • 3 Wakefield D, McCluskey P, Wildner G. et al. Inflammatory eye disease: Pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: Recommendations from an expert committee. Autoimmun Rev 2017; 16: 213-222
    CrossrefPubMedGoogle Scholar
  • 4 Lee RWJ, Schewitz LP, Nicholson LB. et al. Steroid refractory CD4+ T cells in patients with sight-threatening uveitis. Invest Ophthalmol Vis Sci 2009; 50: 4273-4278
    CrossrefPubMedGoogle Scholar
  • 5 Jabs DA, Rosenbaum JT. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2001; 131: 679
    CrossrefPubMedGoogle Scholar
  • 6 Wakefield D, Herbort CP, Tugal-Tutkun I. et al. Controversies in ocular inflammation and immunology laser flare photometry. Ocul Immunol Inflamm 2010; 18: 334-340
    CrossrefPubMedGoogle Scholar
  • 7 Cordero-Coma M, Salazar-Méndez R, Yilmaz T. Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues. Expert Opin Drug Saf 2015; 14: 1071-1086
    CrossrefPubMedGoogle Scholar
  • 8 Kruh J, Foster CS. Corticosteroid-sparing agents: conventional systemic immunosuppressants. Dev Ophthalmol 2012; 51: 29-46
    PubMedGoogle Scholar
  • 9 Pasadhika S, Kempen JH, Newcomb CW. et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 2009; 148: 500-509.e2
    CrossrefPubMedGoogle Scholar
  • 10 Kaçmaz RO, Kempen JH, Newcomb C. et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010; 117: 576-584
    CrossrefPubMedGoogle Scholar
  • 11 Pujari SS, Kempen JH, Newcomb CW. et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 2010; 117: 356-365
    CrossrefPubMedGoogle Scholar
  • 12 Lee K, Bajwa A, Freitas-Neto CA. et al. A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I. Expert Opin Pharmacother 2014; 15: 2141-2154
    CrossrefPubMedGoogle Scholar
  • 13 Simonini G, Cimaz R, Jones GT. et al. Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: The current evidence from a systematic review. Semin Arthritis Rheum 2015; 45: 238-250
    CrossrefPubMedGoogle Scholar
  • 14 Jabs DA, Nussenblatt RB, Rosenbaum JT. et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-516
    CrossrefPubMedGoogle Scholar
  • 15 Goyal A, Goyal K, Merola JF. Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists. Am J Clin Dermatol 2015; 16: 179-195
    CrossrefPubMedGoogle Scholar
  • 16 Warnatz K, Goldacker S, Gause AM. et al. [Vaccination recommendations of the Commission for Pharmacotherapy of the German Society of Rheumatology]. Z Rheumatol 2013; 72: 687-689
    CrossrefPubMedGoogle Scholar
  • 17 Wakefield D. Does cyclophosphamide still have a role in the treatment of severe inflammatory eye disease?. Ocul Immunol Inflamm 2014; 22: 306-310
    CrossrefPubMedGoogle Scholar
  • 18 Joshi L, Talat L, Yaganti S. et al. Outcomes of changing immunosuppressive therapy after treatment failure in patients with noninfectious uveitis. Ophthalmology 2014; 121: 1119-1124
    CrossrefPubMedGoogle Scholar
  • 19 Kempen JH, Daniel E, Dunn JP. et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009; 339: b2480
    CrossrefPubMedGoogle Scholar
  • 20 Østensen M, Förger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol 2009; 5: 382-390
    CrossrefPubMedGoogle Scholar
  • 21 Götestam Skorpen C, Hoeltzenbein M, Tincani A. et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75: 795-810
    CrossrefPubMedGoogle Scholar
  • 22 Viktil KK, Engeland A, Furu K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 2012; 41: 196-201
    CrossrefPubMedGoogle Scholar
  • 23 Götestam Skorpen C, Lydersen S, Gilboe IM. et al. Disease activity during pregnancy and the first year postpartum in women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2017; 69: 1201-1208
    CrossrefPubMedGoogle Scholar
  • 24 Flint J, Panchal S, Hurrell A. et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2016; 55: 1693-1697
    CrossrefPubMedGoogle Scholar
  • 25 Simonini G, Bracaglia C, Cattalini M. et al. Predictors of relapse after discontinuing systemic treatment in childhood autoimmune chronic uveitis. J Rheumatol 2017; 44: 822-826
    CrossrefPubMedGoogle Scholar
  • 26 Burmester GR, Kivitz AJ, Kupper H. et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 2015; 74: 1037-1044
    CrossrefPubMedGoogle Scholar